Navidea Biopharmaceuticals Announces the Extension of Plan Designed to Protect NOLs and Other Tax Assets
Navidea Biopharmaceuticals, Inc. ("Navidea" or the "Company") today announced that its Board of Directors has elected to extend the Company's Section 382 Rights Agreement (the "Section 382 Rights Plan"). Originally adopted on April 7, 2022, and set to expire on April 6, 2025, the plan has now been extended to April 7, 2027.
The Section 382 Rights Plan is designed to safeguard Navidea's ability to utilize its net operating loss carryforwards ("NOLs") and other tax assets. As of December 31, 2024, Navidea had approximately $170 million in U.S. federal NOLs and approximately $9 million in R&D tax credits that may be used to offset future taxable income. However, these valuable tax attributes
